STOCK TITAN

Karyopharm Therapeutics Inc - KPTI STOCK NEWS

Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.

Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.

Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.

Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced on June 2, 2021, that the UK's Medicines & Healthcare Products Regulatory Agency granted conditional marketing authorization for NEXPOVIO® (selinexor) in combination with dexamethasone to treat multiple myeloma in adult patients who have undergone at least four prior therapies. This authorization is based on positive results from the Phase 2b STORM study, which reported a 26% overall response rate in heavily pretreated patients. Continued authorization will depend on confirming clinical benefits in further trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
none
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced on June 1, 2021, the grant of stock options totaling 24,600 shares to six newly-hired employees as an inducement related to their employment. The options were granted at an exercise price of $9.28 per share, equal to KPTI's closing stock price on May 28, 2021. Each option will vest over four years, with the first 25% vesting on the one-year anniversary of employment. If a 'change in control event' occurs, options may become immediately exercisable upon certain termination conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
none
-
Rhea-AI Summary

On May 26, 2021, Karyopharm Therapeutics (Nasdaq: KPTI) announced that CEO Richard Paulson will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference. The event is scheduled for June 2, 2021, at 9:30 a.m. ET. A live webcast can be accessed through the Investor section of the company's website, with a replay available for 30 days post-event. Karyopharm focuses on pioneering novel cancer therapies, including its lead compound XPOVIO® (selinexor), approved for multiple hematologic malignancies in the U.S. and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
conferences
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced the selection of sixteen abstracts for virtual presentation at the ASCO Annual Meeting from June 4-8, 2021. Key highlights include clinical data on XPOVIO® (selinexor) from pivotal studies, showcasing its efficacy in treating multiple myeloma and other cancers. The presentations feature subgroup analyses from the Phase 3 BOSTON study and updates from various combination studies, emphasizing the potential of XPOVIO in overcoming treatment resistance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
none
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced the grant of stock options for 55,300 shares to seven new employees as an inducement for joining the company. The options have an exercise price of $9.34, based on the stock's closing price on April 30, 2021. Each option vests over four years, with the first 25% vesting after one year. These options may be fully exercised if employment is terminated for 'good reason' or without 'cause' within one year of a change in control event. Karyopharm focuses on developing novel cancer therapies, including its lead drug, XPOVIO®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.17%
Tags
none
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) reported first-quarter 2021 results, showing a net product revenue of $21.7 million, up 35% year-over-year. The company highlighted a leadership transition with Richard Paulson appointed as the new CEO. The ongoing U.S. commercialization of XPOVIO reflects a significant increase in prescription demand, with approximately 1,170 prescriptions filled, marking a 17% increase from Q4 2020. Karyopharm anticipates top-line data from the Phase 3 SIENDO study by year-end and expects a decision from the European Commission on NEXPOVIO in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) appointed Richard Paulson as President and Chief Executive Officer effective May 3, 2021, succeeding Michael G. Kauffman and Sharon Shacham. Paulson, who has extensive biopharmaceutical experience and previously served as CEO of Ipsen North America, aims to enhance Karyopharm's commercialization efforts and expand the reach of its lead product, XPOVIO. Kauffman transitions to Senior Clinical Advisor, focusing on clinical developments. The leadership change is positioned as essential for driving growth and innovation at a pivotal moment for the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
management
-
Rhea-AI Summary

Karyopharm Therapeutics (NASDAQ:KPTI) will report its first quarter 2021 financial results on May 3, 2021. The company's management will host a conference call at 8:30 a.m. ET on the same day to discuss the results and provide updates. Karyopharm is known for its innovative cancer therapies, particularly its lead compound, XPOVIO (selinexor), which is approved for multiple indications and has received conditional marketing authorization in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences earnings
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) has announced the validation of its Type II Variation Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for NEXPOVIO® (selinexor). This application aims to expand the use of NEXPOVIO in combination with Velcade® and low-dose dexamethasone for treating adult patients with multiple myeloma who have undergone at least one prior therapy. The decision is based on encouraging results from the Phase 3 BOSTON study. The EMA's review is expected to conclude in Q4 2021, signifying a vital step in enhancing treatment options for multiple myeloma in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
none
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced the publication of health-related quality of life (HRQoL) data from the Phase 3 SEAL study, evaluating selinexor in advanced unresectable dedifferentiated liposarcoma (DDLPS). The study showed a statistically significant improvement in progression-free survival (PFS) and notable reductions in pain for patients treated with selinexor compared to placebo. With 285 patients involved, the results underscore selinexor's potential to provide meaningful clinical benefits, despite being unapproved for DDLPS. Adverse effects included manageable cytopenias and gastrointestinal issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.94%
Tags
Karyopharm Therapeutics Inc

Nasdaq:KPTI

KPTI Rankings

KPTI Stock Data

42.42M
8.01M
6.86%
48.47%
12.56%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEWTON